Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Mallinckrodt
Harvard Business School
Cipla
Medtronic
AstraZeneca
US Army
Farmers Insurance
Federal Trade Commission

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: RE41884

« Back to Dashboard

Summary for Patent: RE41884
Title:Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
Abstract:Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.
Inventor(s): de Garavilla; Lawrence (Downington, PA), Liversidge; Elaine (West Chester, PA), Liversidge; Gary G. (West Chester, PA)
Assignee: Elan Pharma International Limited (Co. Clare, IR)
Application Number:12/027,100
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent RE41884

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE41884

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 7117196 ➤ Sign Up
Canada 2232879 ➤ Sign Up
European Patent Office 0859604 ➤ Sign Up
European Patent Office 2275094 ➤ Sign Up
Japan 2001518059 ➤ Sign Up
World Intellectual Property Organization (WIPO) 9711686 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
McKesson
Daiichi Sankyo
Dow
McKinsey
Medtronic
Farmers Insurance
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot